Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome

Journal of Endocrinology

Volumn 184, Issue 1, 2005, Pages 233-239

  Ortega Gonzalez C ^a   Cardoza, L ^a   Coutino B ^a   Hidalgo, R ^a   Arteaga Troncoso, G ^a   Parra, A ^a  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

FICONAX; GLUCOSE; INSULIN; METFORMIN; METOCLOPRAMIDE; PIOGLITAZONE; PRAMOTIL; PROLACTIN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIET RESTRICTION; DIET THERAPY; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MENSTRUAL CYCLE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; PROLACTIN; THIAZOLIDINEDIONES;

EID: 13444256032     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.05844     Document Type: Article

References (35)

1. Albareda M, Rodríguez-Espinosa J, Murugo M, de Leyva A & Corcoy R 2000 Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43 1507-1511.
2. Baillargeon JP, Iuorno MJ & Nestler JE 2002 Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome. Current Opinion in Endocrinology and Diabetes 9 303-311.
3. Ben-Jonathan N 1985 Dopamine: a prolactin-inhibiting hormone. Endocrine Reviews 6 564-589.
4. Birnbacher R, Scheibenreiter S, Blau N, Bieglmayer C, Frisch H & Waldhauser F 1998 Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl. Pediatric Research 43 472-477.
5. Burghen GA, Givens JR & Kitabchi AE 1980 Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 50 113-116.
6. Cincotta AH & Meier AH 1996 Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19 667-670.
7. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Review 18 774-800.
8. Ehrmann DA, Cavaghan MK, Imperial J, Sturgis J, Rosenfield RL & Polonsky KS 1997a Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82 524-530.
9. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL & Polonsky KS 1997b Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82 2108-2116.
10. Fonseca V 2003 Effect of thiazolidinediones on body weight in patients with diabetes mellitus. American Journal of Medicine 115 Suppl 42-48.
11. Harborne I, Fleming R, Lyall H, Norman J & Sattar N 2003 Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361 1894-1901.
12. Hernández I, Parra A, Méndez I, Cabrera V, Cravioto MC, Mercado M, Díaz Sánchez V & Larrea F 2000 Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome. Archives of Medical Research 31 216-222.
13. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 85 2402-2410.
14. Leblanc H, Lacheling GCL, Abu-Fadil S & Yen SSC 1976 Effects of dopamine infusion on pituitary hormone secretion in humans. Journal of Clinical Endocrinology and Metabolism 43 668-674.
15. Lobo RA 2003 What are the key features of importance in polycystic ovary syndrome? Fertility and Sterility 80 259-261.
16. Luciano AA, Chapler FK & Sherman BM 1984 Hyperprolactinemia in polycystic ovary syndrome. Fertility and Sterility 41 719-725.
17. Parra A, Ramírez A & Espinosa de los Monteros A 1994 Fasting glucose/insulin ratio. An index to differentiate normo from hyperinsulinemic women with polycystic ovary syndrome. Revista de Investigación Clinica (México) 46 363-368.
18. Parra A, Barrón J, Sinibaldi J, Coria I & Espinosa de los Monteros A 1997 Differences in the metoclopramide-induced prolactin release related to age at first full-term pregnancy or nulliparity. Human Reproduction 12 214-219.
19. Parra A, Ramírez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I, Angeles A, Pérez-Romano B, Ruíz-Argü elles G & Ruíz-Argúelles B 2001 Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clinical Endocrinology (Oxford) 54 731-738.
20. Polson DW, Mason HD & Franks S 1987 Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome. Clinical Endocrinology 26 197-203.
21. Prelevic GM, Wurzburger MI & Peric LA 1988 Metoclopramide effect on serum prolactin, LH and FSH in patients with polycystic ovary syndrome. Journal of Endocrinological Investigation 11 255-259.
22. Quigley ME, Judd SJ, Gilliand GB & Yen SSC 1979 Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. Journal of Clinical Endocrinology and Metabolism 52 231-234.
23. Quigley ME, Rakoff JS & Yen SSC 1981 Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 52 231-234.
24. Rosenfield RL 1997 Is polycystic ovary syndrome a neuroendocrine or an ovarian disorder? Clinical Endocrinology 47 423-424.
25. Shoupe D & Lobo RA 1984 Evidence for altered catecholamine metabolism in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 150 566-571.
26. Sinha YN & Sorenson RL 1993 Differential effects of glycosylated and nonglycosylated prolactin on islet cell division and insulin secretion. Proceedings of the Society for Experimental Biology and Medicine 203 123-126.
27. Sorenson RL & Parson JA 1985 Insulin secretion in mammosomatotropic tumor bearing and pregnant rats: a role for lactogens. Diabetes 34 337-341.
28. Sorenson RL & Stout LE 1995 Prolactin receptors and JAK 2 in islets of Langerhans: an immunohistochemical analysis. Endocrinology 136 4092-4098.
29. Sorenson RL, Brelje TC, Hegre OD, Marshall S, Anaya P & Sheridan J 1987 Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet β-cells. Endocrinology 121 1447-1453.
30. Tai MM 1994 A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17 152-154.
31. Takemoto M, Morishita H, Higuchi K, Yoshida J & Aono T 1994 Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin releasing hormone in secondary amenorrhoeic women. Human Reproduction 9 800-805.
32. Taylor AE, Mc Court B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D & Hall JE 1997 Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82 2248-2256.
33. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19 41-47.
34. Uvnas-Moberg K, Ahlenius S, Alster P & Hillegaart V 1996 Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 63 269-274.
35. Velardo A, Pantalioni M, Ziromi C, Zizzo G & Marrama P 1991 Evidence of altered dopamine modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome. Hormone Research 35 4-7.